Tim Loh

Adidas AG raised its annual profit target for the third quarter in a row amid the sustained boom for retro sneakers like the Samba and more sales from its shrinking stockpile of Yeezy footwear.

Sanofi’s profit rose on demand for its flu vaccines and a shot for a common respiratory virus, as well as further growth in its blockbuster skin and asthma therapy Dupixent.

Earnings per share excluding some items reached €2.86 ($3.10) in the third quarter, exceeding analysts’ estimates.

(Bloomberg) -- Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.

Bayer AG cut its profit outlook for the year on stubbornly low prices for agriculture products, including the controversial weedkiller Roundup.

Federer-backed company quarterly sales beat estimates Executive says running is among fastest-growing categories

On Holding AG raised its sales outlook for the year as the Swiss sneaker maker steps up its competition with bigger rivals such as Adidas AG and Nike Inc.

Bayer AG shares plunged to the lowest in two decades after the German conglomerate cut profit guidance for this year and said earnings will probably fall in 2025.

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.

Adidas AG raised its annual profit target for the third quarter in a row amid the sustained boom for retro sneakers like the Samba and more sales from its shrinking stockpile of Yeezy footwear.